26.12.2011                      30.Kislev. 5772                       Channuka 6                      Rosch Chodesch 1

Arzneimittel-Industrie:

Teva: Making the leap from adolescence to solid maturity

Over and above improving transparency, Teva's conference call with analysts after releasing its 2012 forecast involved matching-up expectations for the short term and the long term as well.

One of the prevailing market sentiments regarding Teva Pharmaceutical Industries has been that its communication with the capital market could stand improvement. Teva management made a major effort to rectify this by moving up its 2012 forecast two months and providing more details than ever before about its operations in the next 12 months, including sales forecasts for seven proprietary drugs and geographic and product line breakdowns of sales turnover.
Over and above improving transparency, Teva's conference call with analysts after releasing its 2012 forecast involved matching-up expectations for the short term and the long term as well. Teva management described its forecast as conservative and cautious partly in consideration of the global economic outlook, but it could also be assumed as partially deriving from lessons learned from the past….